查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984007

口服避孕藥市場：按劑型、包裝、給藥週期、最終用戶和分銷管道分類的全球市場預測，2026-2032年

Contraceptive Pills Market by Formulation, Packaging, Dosage Cycle, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年避孕藥具市場價值為 221.2 億美元，預計到 2026 年將成長至 235.7 億美元，複合年成長率為 6.68%，到 2032 年將達到 347.9 億美元。

主要市場統計數據
基準年 2025 221.2億美元
預計年份：2026年 235.7億美元
預測年份 2032 347.9億美元
複合年成長率 (%) 6.68%

策略性介紹概述了影響避孕策略的臨床創新、監管壓力、供應鏈現實和患者獲取挑戰。

本執行摘要全面概述了目前影響避孕藥具研發、分銷和病患取得的趨勢。這一領域的特點是臨床創新日新月異、法律規範不斷加強、消費者對便利性和個人化的偏好日益成長，以及從生產商到最終用戶的流程發生顯著變化。臨床、商業和政策領域的相關人員必須在安全性、有效性、可負擔性和供應穩定性之間取得平衡，同時應對人們對生殖健康政策和取得途徑日益成長的擔憂。

分析臨床、監管、數位化和供應方面的變革，這些變革正在重新定義避孕藥的價值是如何創造和傳遞給使用者的。

避孕領域正經歷著許多變革，這些變革正在改變其競爭定位和策略重點。臨床創新透過最佳化荷爾蒙平衡和給藥方案，提升了產品的治療效果和生活方式適應性，優先考慮耐受性和月經週期柔軟性。除了這些臨床進展外，旨在提高用藥依從性、支持遠端處方以及將患者報告結果納入上市後安全性監測的數位健康干預措施也蓬勃發展。這些因素共同作用，正在改變價值的定義，使其不再只專注於療效，而是更重視使用者體驗、便利性和長期安全性證據。

對 2025 年關稅措施將如何引發採購、製造和分銷方面的調整，以及它們將如何重組營運風險和供應商策略進行全面評估。

2025年關稅的實施對整個避孕藥具價值鏈造成了多方面的壓力，促使製造商、經銷商和採購團隊採取策略性應對措施。新的關稅針對活性成分和包裝材料的投入成本，特別是海外採購的原料，改變了全球採購的成本會計基礎。因此，製造商加快了供應商多元化策略，尋求替代原料來源，並在某些情況下考慮將生產地點設在更靠近市場的地區，以減輕進口關稅的影響。這些調整對採購計畫、合約談判和庫存政策產生了連鎖反應，導致前置作業時間假設和供應商關係管理發生變化。

多維細分分析將配方、包裝、劑量、定價、分銷和人口統計群體與策略槓桿和產品定位聯繫起來。

市場區隔為理解差異化的臨床、包裝、給藥方式、定價、分銷和人口統計策略最有可能帶來競爭優勢的領域提供了一個切實可行的觀點。基於製劑，我們檢驗了複方口服避孕藥和單孕激素口服避孕藥的市場趨勢。在複方製劑中，產品設計進一步細分為雙相、單相、四相和三相方案，單相產品則在低劑量、標準劑量和超低劑量階段進行評估，以明確耐受性和副作用之間的權衡。這種製劑分類指南新進業者和成熟品牌確定研發重點和臨床定位。

將美洲、歐洲、中東和非洲以及亞太地區的管理體制、流通結構和病患行為連結起來的區域分析。

區域趨勢透過法規環境、公共衛生重點、分銷基礎設施和消費者行為來影響產品策略。在美洲，政策辯論和改善藥品可及性的舉措與成熟的零售和數位藥房管道並存。該地區重點關注生殖醫學計畫的可近性、臨床醫生的處方實踐以及與支付方的談判，這些因素會影響藥品在藥品採納清單上的排名和經銷夥伴關係。在該地區運營的製造商優先考慮遵守嚴格的藥品安全監測標準，並利用數位化用藥依從性工具和遠端醫療整合來支持患者的持續參與和醫療服務提供者的參與。

公司策略概述，重點在於配方創新、供應鏈韌性、全通路分銷和基於證據的差異化。

避孕藥領域的主要企業正在推行差異化策略，涵蓋臨床創新、產品組合精簡和垂直整合。一些生產商致力於改進配方以提高耐受性和依從性，而另一些生產商則優先開發具有成本競爭力的學名藥藥，以確保與大型連鎖藥局和機構買家簽訂分銷合約。隨著企業努力降低生產風險並縮短改良產品的上市時間，與契約製造生產商和專業包裝公司建立策略合作夥伴關係正變得越來越普遍。

為高階主管提供切實可行的策略和營運建議，以增強其整個產品組合的產品差異化、供應鏈韌性、數位化分銷和支付方參與度。

優先推進將臨床差異化與以使用者為中心的益處相結合的配方和產品開發舉措，並投資於符合臨床醫生指導和患者生活方式偏好的耐受性研究和長期給藥方案。同時，系統化供應商多元化策略，並確保關鍵原料的替代認證來源，以降低關稅風險和運輸延誤。加強供應商認證和品質保證流程，確保新的採購結構不會影響監管合規性或病人安全。

對構成分析基礎的初級和二級調查的綜合方法、檢驗過程和品管進行透明的解釋。

本報告的研究基礎是將一手質性研究與系統性的二手證據結合，以提供平衡且切實可行的見解。一手研究包括對臨床醫生、藥劑師、採購專家、生產經理和監管專家進行結構化訪談，以了解實際操作情況和新興的臨床偏好。這些對話旨在闡明採購、處方和分銷方面的實際挑戰，以及病患依從性和安全性監測的問題。

簡潔扼要的總結強調了將臨床創新、供應彈性和分銷靈活性相結合的整合策略，以實現長期領先地位。

目前避孕藥的發展正處於十字路口，臨床療效的提升、監管的日益嚴格、供應鏈的韌性增強以及分銷模式的演變交織在一起。製劑科學的進步和給藥方式的柔軟性正在拓展臨床選擇，並改善以使用者為中心的治療效果。同時，數位醫療和遠端醫療的進步正在創造新的途徑和機制，以支持患者的用藥依從性。然而，地緣政治和貿易的發展也凸顯了全球採購的脆弱性，促使企業進行策略轉型，轉向供應商多角化和探索區域生產。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 以劑型分類的口服避孕藥市場

  • 複方藥片
    • 雙相
    • 單相型
      • 低劑量
      • 標準劑量
      • 超低劑量
    • 四相型
    • 三相型
  • 僅含黃體素的避孕藥

第9章 口服避孕藥市場：依包裝類型分類

  • 泡殼包裝
  • 帶狀包裝

第10章：以劑量週期分類的口服避孕藥市場

  • 21天給藥方案
  • 28天給藥方案
  • 延長週期

第11章 口服避孕藥市場：依最終用戶分類

  • 青少年
  • 成人

第12章 口服避孕藥市場：依通路分類

  • 診所藥房
  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第13章 口服避孕藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口服避孕藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 口服避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國口服避孕藥市場

第17章：中國口服避孕藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Afaxys Pharma, LLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bionpharma Inc.
  • Cipla Limited
  • Combe Incorporated
  • Dr. Reddy's Laboratories（DRL）
  • Gedeon Richter PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Julie Product Inc.
  • Lupin Limited
  • Mankind Pharma Ltd.
  • McKesson Medical-Surgical Inc.
  • Merck & Co., Inc.
  • Perrigo Company plc
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Sun Pharmaceutical Industries Limited
  • Syzygy Healthcare Solutions, LLC
  • Teva Pharmaceuticals
  • Viatris Inc.
  • Xiromed, LLC
Product Code: MRR-A579C4315A23

The Contraceptive Pills Market was valued at USD 22.12 billion in 2025 and is projected to grow to USD 23.57 billion in 2026, with a CAGR of 6.68%, reaching USD 34.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.12 billion
Estimated Year [2026] USD 23.57 billion
Forecast Year [2032] USD 34.79 billion
CAGR (%) 6.68%

A strategic introduction that frames clinical innovation, regulatory pressures, supply-chain realities, and patient access imperatives shaping contraceptive pill strategy

This executive summary introduces a comprehensive synthesis of contemporary dynamics shaping contraceptive pill development, distribution, and patient access. The landscape is defined by rapid clinical innovation, evolving regulatory oversight, shifting consumer preferences toward convenience and personalization, and material changes in how products move from manufacturer to end user. Stakeholders across clinical, commercial, and policy domains must balance safety, efficacy, affordability, and supply resilience while responding to heightened attention on reproductive health policy and access.

Over the past several cycles, progress in formulation science has expanded options across hormonal profiles and dosing regimens, while digital channels and telehealth have redefined points of care and adherence support. Concurrently, manufacturers and distributors face intensified scrutiny on quality and sourcing as global supply chains confront geopolitical pressures. This introduction frames the subsequent sections by highlighting the intersection of clinical differentiation, regulatory compliance, supply-chain management, and consumer-directed distribution. The intent is to equip decision-makers with a clear, evidence-informed foundation for strategic planning and operational adaptation.

An analysis of clinical, regulatory, digital, and supply-side shifts that are redefining how contraceptive pill value is created and delivered to users

The contraceptive pill sector is undergoing several transformative shifts that are altering competitive positioning and strategic priorities. Clinical innovation is broadening the therapeutic and lifestyle attributes of products through refined hormonal balances and dosing regimens that prioritize tolerability and cycle flexibility. These clinical developments are complemented by a surge in digital health interventions aimed at improving adherence, facilitating remote prescribing, and integrating patient-reported outcomes into post-market safety surveillance. Together, these forces are reshaping how value is defined beyond efficacy alone, moving toward a model that prizes user experience, convenience, and longitudinal safety evidence.

Regulatory and policy dynamics also constitute a significant axis of change. Authorities are increasingly focused on pharmacovigilance, product traceability, and supply-chain transparency, which has prompted manufacturers to re-evaluate sourcing and quality assurance protocols. At the same time, payer and provider behaviors are adapting to different cost-containment and access priorities, with an emphasis on ensuring equitable access across diverse demographic segments. Finally, supply-chain resilience has become a board-level concern; firms are investing in diversified suppliers, regional manufacturing capacity, and advanced inventory management to mitigate disruption. The cumulative effect of these shifts is a market environment that rewards agility, evidence-driven product differentiation, and tightly managed regulatory compliance.

A comprehensive assessment of how tariff actions in 2025 triggered procurement, manufacturing, and distribution adaptations reshaping operational risk and supplier strategies

The introduction of tariffs in 2025 has exerted multi-dimensional pressure across the contraceptive pill value chain, prompting strategic responses from manufacturers, distributors, and procurement teams. Input costs for active pharmaceutical ingredients and packaging materials, particularly those sourced internationally, have been subjected to new duties that changed the calculus of global procurement. As a result, manufacturers have accelerated supplier diversification strategies, sought alternative raw-material sources, and in some cases considered closer-to-market production footprints to mitigate exposure to import levies. These adjustments have flowed through procurement plans, contractual negotiations, and inventory policies, altering lead-time assumptions and supplier relationship management.

Beyond direct cost implications, tariffs have catalyzed operational and commercial shifts. Firms have increased engagement with regulatory authorities to expedite approvals for alternative suppliers and have invested in quality assurance to facilitate qualification of new supply partners. Distribution networks have been reassessed to prioritize channels that can absorb operational complexity while preserving service levels. Payers and wholesalers are likewise recalibrating procurement strategies to balance cost containment with supply reliability, and pharmacies are adapting their assortment and stocking practices. In this context, tariff-induced change functions as a structural stress test that accelerates localization, elevates the importance of supply-chain transparency, and compels a reappraisal of contract design and contingency planning across the ecosystem.

A multidimensional segmentation analysis mapping formulation, packaging, dosing, pricing, distribution, and demographic cohorts to strategic levers and product positioning

Segmentation provides a practical lens to understand where differentiated clinical, packaging, dosing, pricing, distribution, and demographic strategies are most likely to yield competitive advantage. Based on formulation, the landscape is examined across combination pill and progestin-only pill options. Within combination therapies, product design is further stratified into biphasic, monophasic, quadriphasic, and triphasic regimens, and monophasic offerings are assessed at low dose, standard dose, and ultra-low dose gradations to clarify tolerability and side-effect trade-offs. This formulation taxonomy informs development priorities and clinical positioning for both newer entrants and legacy brands.

Based on packaging, products are categorized across blister pack and strip pack formats, where packaging choices influence adherence support, dispensing preferences, and waste management considerations. Based on dosage cycle, regimens include 21-day, 28-day, and extended-cycle options, each aligning to different user lifestyle preferences and clinical guidance. Based on pricing tier, the competitive dynamic spans branded and generic offerings, which intersect with payer contracting and formulary placement strategies. Based on distribution channel, the ecosystem includes clinic pharmacy, hospital pharmacy, online pharmacy, and retail pharmacy, with retail pharmacy further subdivided into chain pharmacy and independent pharmacy, a distinction that affects stocking decisions and promotional approaches. Based on end user, segmentation addresses adolescents, adults, and mature adults, with adults further detailed across 20-24, 25-29, and 30-34 cohorts to capture life-stage needs, fertility planning behaviors, and adherence drivers. Together, these segmentation lenses enable prioritization of product development, channel alignment, and messaging frameworks tailored to distinct clinical and commercial use cases.

Regionally calibrated intelligence that links regulatory regimes, distribution structures, and patient behaviors across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape product strategy through regulatory environments, public health priorities, distribution infrastructure, and consumer behavior. In the Americas, policy debates and access initiatives coexist with mature retail and digital pharmacy channels; this region emphasizes reproductive health access programs, clinician-prescribing practices, and payer negotiations that influence formulary positioning and distribution partnerships. Manufacturers operating here prioritize compliance with stringent pharmacovigilance standards and leverage digital adherence tools and telehealth integrations to support patient retention and clinician engagement.

In Europe, Middle East & Africa, heterogeneity is pronounced; regulatory regimes vary from highly centralized approval pathways to fragmented national systems, and distribution infrastructures range from robust hospital and retail networks to emerging online pharmacy ecosystems. This region requires nuanced market-entry strategies that balance centralized clinical evidence generation with localized regulatory and reimbursement tactics. The Asia-Pacific region presents a combination of rapid digital adoption and growing domestic manufacturing capability, where demand patterns are shaped by demographic trends, urbanization, and expanding pharmacy e-commerce. Across all regions, stakeholders are responding to supply-chain considerations and local policy shifts while innovating in packaging and service delivery models to meet distinct regional needs.

An executive synthesis of corporate strategies emphasizing formulation innovation, supply resilience, omnichannel distribution, and evidence-based differentiation

Leading companies in the contraceptive pill arena are pursuing differentiated strategies that span clinical innovation, portfolio rationalization, and vertical integration. Several manufacturers are investing in formulation upgrades to improve tolerability and adherence, while others are prioritizing cost-competitive generics to secure distribution agreements with large pharmacy chains and institutional buyers. Strategic partnerships with contract manufacturers and specialty packaging firms are increasingly common as firms seek to de-risk production and accelerate time-to-shelf for reformulated assets.

Commercially, organizations are experimenting with omnichannel distribution models that combine clinic-based initiation, online follow-up, and subscription-based fulfillment to enhance retention. Similarly, companies are strengthening pharmacovigilance capabilities and real-world evidence programs to support regulatory submissions and payer discussions. On the supply side, firms with flexible manufacturing footprints and robust supplier qualification programs have improved operational resilience, enabling them to respond more quickly to procurement disruptions and to qualify alternative APIs and packaging sources. Collectively, these corporate moves underscore a broader industry emphasis on agility, integrated data capabilities, and patient-centric service models.

Practical strategic and operational recommendations for executives to enhance product differentiation, supply resilience, digital distribution, and payer engagement across portfolios

Prioritize formulation and product development initiatives that align clinical differentiation with user-centric benefits; invest in tolerability profiles and extended-cycle options that respond to clinician guidance and patient lifestyle preferences. Simultaneously, codify supplier diversification strategies and establish alternative qualified sources for critical inputs to reduce tariff exposure and shipment delays. Strengthen supplier qualification and quality assurance processes so that new sourcing arrangements do not compromise regulatory compliance or patient safety.

Elevate digital and distribution capabilities by integrating telehealth-friendly prescribing workflows and subscription fulfillment models that improve adherence and retention. Engage proactively with payers and health systems to demonstrate value through real-world safety and adherence data rather than relying solely on traditional clinical endpoints. Finally, design commercial models that account for regional regulatory variance and channel nuances, tailoring packaging and pricing approaches to local distribution structures while preserving the ability to scale successful programs across adjacent markets.

A transparent description of the integrated primary and secondary research approach, validation processes, and quality controls underpinning the analysis

The research underpinning this report integrates primary qualitative inquiry with a systematic secondary evidence synthesis to deliver balanced, actionable insights. Primary engagement includes structured interviews with clinicians, pharmacists, procurement specialists, manufacturing leaders, and regulatory experts to capture operational realities and emergent clinical preferences. These conversations are designed to surface practical challenges in sourcing, prescribing, and distribution as well as perspectives on patient adherence and safety monitoring.

Secondary research involved comprehensive review of peer-reviewed clinical literature, regulatory guidance documents, patent and approval records, industry technical bulletins, and publicly available corporate disclosures to validate thematic findings and ensure alignment with current standards of care and regulatory expectations. Data triangulation and cross-validation were applied throughout to reconcile conflicting viewpoints and to highlight areas where evidence is robust versus where uncertainty remains. Quality controls included methodological audits, expert review panels, and iterative validation with select interviewees to ensure fidelity to real-world practice and operational constraints.

A concise concluding synthesis emphasizing integrated strategies that combine clinical innovation, supply resilience, and distribution agility for long-term leadership

The contraceptive pill landscape is at an inflection point where clinical refinement, regulatory rigor, supply-chain resilience, and evolving distribution models intersect. Progress in formulation science and dosing flexibility expands clinical options and enhances user-centered outcomes, while digital health and telemedicine pathways are creating new access routes and adherence support mechanisms. At the same time, geopolitical and trade developments have highlighted vulnerabilities in global sourcing, catalyzing a strategic shift toward supplier diversification and regional manufacturing considerations.

For senior leaders, the imperative is to adopt an integrated approach that aligns product innovation with operational resilience and channel-first commercial models. Organizations that combine rigorous quality systems, adaptable supply chains, and evidence-driven commercialization will be best positioned to respond to policy shifts, competitive pressures, and changing patient expectations. Strategic investments made today in formulation, data infrastructure, and distribution orchestration will determine which firms lead the next phase of value creation in contraceptive care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Pills Market, by Formulation

  • 8.1. Combination Pill
    • 8.1.1. Biphasic
    • 8.1.2. Monophasic
      • 8.1.2.1. Low Dose
      • 8.1.2.2. Standard Dose
      • 8.1.2.3. Ultra-Low Dose
    • 8.1.3. Quadriphasic
    • 8.1.4. Triphasic
  • 8.2. Progestin-Only Pill

9. Contraceptive Pills Market, by Packaging

  • 9.1. Blister Pack
  • 9.2. Strip Pack

10. Contraceptive Pills Market, by Dosage Cycle

  • 10.1. 21-Day Regimen
  • 10.2. 28-Day Regimen
  • 10.3. Extended Cycle

11. Contraceptive Pills Market, by End User

  • 11.1. Adolescents
  • 11.2. Adults

12. Contraceptive Pills Market, by Distribution Channel

  • 12.1. Clinic Pharmacy
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy
    • 12.4.1. Chain Pharmacy
    • 12.4.2. Independent Pharmacy

13. Contraceptive Pills Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Contraceptive Pills Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Contraceptive Pills Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Contraceptive Pills Market

17. China Contraceptive Pills Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Afaxys Pharma, LLC
  • 18.7. Amneal Pharmaceuticals, Inc.
  • 18.8. Apotex Inc.
  • 18.9. Aurobindo Pharma Limited
  • 18.10. Bayer AG
  • 18.11. Bionpharma Inc.
  • 18.12. Cipla Limited
  • 18.13. Combe Incorporated
  • 18.14. Dr. Reddy's Laboratories (DRL)
  • 18.15. Gedeon Richter PLC
  • 18.16. Glenmark Pharmaceuticals Limited
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Julie Product Inc.
  • 18.19. Lupin Limited
  • 18.20. Mankind Pharma Ltd.
  • 18.21. McKesson Medical-Surgical Inc.
  • 18.22. Merck & Co., Inc.
  • 18.23. Perrigo Company plc
  • 18.24. Pfizer Inc.
  • 18.25. Piramal Enterprises Ltd.
  • 18.26. Sun Pharmaceutical Industries Limited
  • 18.27. Syzygy Healthcare Solutions, LLC
  • 18.28. Teva Pharmaceuticals
  • 18.29. Viatris Inc.
  • 18.30. Xiromed, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ULTRA-LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY QUADRIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY BLISTER PACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY STRIP PACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 21-DAY REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY 28-DAY REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY EXTENDED CYCLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CLINIC PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINATION PILL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)